Both cell-autonomous and non-cell-autonomous factors contribute to tumor growth and metastasis of melanoma. The function of Caveolin-1 (Cav1), a multifunctional scaffold protein known to modulate several biological processes in both normal tissue and cancer, has been recently investigated in melanoma cancer cells, but its role in the melanoma microenvironment remains largely unexplored. Here, we show that orthotopic implantation of B16F10 melanoma cells in the skin of Cav1KO mice increases tumor growth, and co-injection of Cav1-deficient dermal fibroblasts with melanoma cells is sufficient to recapitulate the tumor phenotype observed in Cav1KO mice. Using indirect co-culture experiments with fibroblasts and melanoma cells combined with cytokine analysis, we found that Cav1-deficient fibroblasts promoted the growth of melanoma cells via enhanced paracrine cytokine signaling. Specifically, Cav1-deficient fibroblasts displayed increased ShhN expression, which heterotypically enhanced the Shh signaling pathway in melanoma cells. In contrast to primary tumor growth, the ability of B16F10 melanoma cells to form lung metastases was significantly reduced in Cav1KO mice. This phenotype was associated mechanistically with the inability of melanoma cells to adhere to and to transmigrate through a monolayer of endothelial cells lacking Cav1. Together, our findings demonstrate that Cav1 may regulate different mechanisms during primary melanoma tumor growth and metastatic dissemination.
INTRODUCTION
Tumors are heterogeneous microenvironments that consist of both neoplastic and nonneoplastic cells (tumor-stroma). Tumor growth and the consequent metastatic dissemination of tumor cells result from continuous reciprocal interactions between cancer cells and their surrounding stroma (1, 2) . Cutaneous melanoma remains the most aggressive type of skin cancer and both cell-autonomous and non cell-autonomous mechanisms are necessary for melanoma growth and metastasis (3) . Recent research, in fact, has demonstrated that stromal cells (fibroblasts and endothelial cells) support the growth and dissemination of melanoma cells by modulating angiogenesis, secreting growth factors and cytokines, and contributing to extracellular matrix (ECM) deposition and degradation (4) . Thus, identifying novel mechanisms critically regulating tumor-stroma interactions may be therapeutically relevant in this type of cancer.
Caveolae are specialized microdomains of the plasma membrane enriched in the scaffold protein Caveolin-1 (Cav1) (5, 6) . Due to the multitude of interacting proteins described, Cav1 has been implicated in the modulation of many biological processes in both normal tissue and cancer (8, 35) . Although much research has primarily focused on determining the function of Cav1 in cancer cells, recent studies have started to investigate the function of Cav1 protein in the tumor microenvironment (9, 10) . Indeed, Cav1 is highly expressed in endothelial cells and fibroblasts, two of the cell types that are normally involved in stromal remodeling during melanoma progression (3) . In addition, the angiogenesis defects (11) and impaired skin wound-healing (12) displayed by Cav1KO mice suggest that loss of Cav1 in the stromal compartment may functionally affect tumor-stromal interactions in melanomagenesis.
To examine this issue we used Cav1KO mice to determine whether stromal Cav1 may affect the growth and metastatic ability of B16F10 melanoma cells. We show that absence of Cav1 promotes the growth of intradermally implanted B16F10 melanoma cells in mice. Indirect co-culture experiments and co-injections of fibroblasts and melanoma cells demonstrate that lack of Cav1 in dermal fibroblasts promotes the growth of melanoma cells in vitro and in vivo via paracrine cytokine signaling. In contrast, the ability of B16F10 cells to form lung metastases in Cav1KO mice was significantly impaired. These results were consistent with the inability of B16F10 cells to transmigrate through a monolayer of HUVEC cells lacking Cav1. Collectively, our data suggest functionally distinct roles for stromal Cav1 in melanoma primary tumor growth and metastasis.
METHODS

Materials
Antibodies and their sources were as follows: Cav1 (N-20), PECAM-1 (M20), eGFP (sc-8334) and Shh(N-19) were from Santa Cruz. Keratin-14 (K14) was from Covance. Rat anti-mouse VCAM1 and ICAM1 were from R&D. Gli-1 was from Cell Signaling. β-Tubulin, was from Sigma and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was from Fitzgerald.
Animal Studies
3-4-month-old Cav1WT (WT), Cav1KO (13) , and Cav2KO (14) C57Bl/6 female mice were used for orthotopic and i.v. injections of B16F10 cells. For co-injection experiments, 3-4-month-old athymic female mice (NCr-Nu; Taconic) were used (15, 16) . All in vivo studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Thomas Jefferson University.
Cell lines
B16F10 and A-375 were from ATCC, while human immortalized dermal foreskin fibroblasts (hTBJ1) were originally from Clontech. Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from ALLCELLS. Only early passages of these cell lines were used in experiments.
Neonatal dermal fibroblasts
Dermal fibroblasts (FB) and primary mouse keratinocytes (MK) were isolated from the skin of newborn mice (1-3-day-old) as described in details by others (18) . FB were suspended in medium with 10% FBS-DMEM (Invitrogen) and initially plated at a density of 5,000 cells/ cm 2 .
Co-injection experiments
WT, Cav1KO and Cav2KO neonatal FB (see above) were intradermally co-injected with 10 5 B16F10 cells in nude mice at 5:1 ratios. Similarly, hTBJ1 fibroblasts were co-injected with human A-375 melanoma cells (19, 20) .
Lentiviral vectors
For lentivirus mediated silencing of the Cav1 gene, pre-designed control shRNAmiR (shCtrl-miR) and shRNAmiRs (shCAV1-miRs) targeting the human CAV1 mRNA (NM_001753.3) were purchased from Invitrogen and subcloned into the pRRLsin.cPPT.hCMV.eGFP.WPRE (LV-eGFP) lentiviral vector (21). The resulting constructs (LV-shCtrl-miR-eGFP and LV-shCAV1-miRs-eGFP) were packaged according to standard protocols (21). Effective CAV1 knockdown in target cells was determined by Western Blot analysis of FACS sorted eGFP positive cells. A lentiviral vector (Lv105-Puro) encoding mCherry cDNA was from Genecopoeia whereas ready to use shCtrl-Puro and shGli-1-Puro (gene ID: 14632) lentiviral particles were from Santa Cruz.
Co-cultures of Fibroblasts and Melanoma cells
Direct cocultures (direct cell-cell contact) were established by seeding 10 4 /cm 2 mCherrylabeled melanoma cells on eGFP-labeled (shCtrl/shCAV1 cells) or on unlabeled FB (1:5 ratios) that had previously been serum-activated as described below for the conditioned medium experiments. 48h or 72h after the initial plating (22) co-cultures were harvested and their relative growth determined by Flow Cytometry analysis (FACS). Transwell cocultures of fibroblasts and melanoma cells (no cell-cell contact) were established as described above by using Transwell inserts with 0.4μm-pore-size membrane inserts (23).
Conditioned medium experiments
Conditioned medium (CM) was collected from dermal FB that were maintained in serum free medium for 48h (SFM). FB were then serum activated by maintaining them for 12h in 10%FBS-DMEM and 24h in 1%FBS-DMEM (24). CM from these cells (SA-CM) was then incubated with melanoma cells for 48h. For Shh-pathway inhibition studies, Cyclopamine (Selleck) or DMSO were added to CM for 48h. Recombinant Shh protein (Peprotech) was used for hedgehog signaling activation in melanoma cells.
Cytokine Array and ELISA
Cytokine array and ELISA for ShhN were performed on FB-CM using commercially available kits from Raybiotech and R&D. Immunohistochemistry S100 (RAb;Dako) immunohistochemical staining of 5μm paraffin embedded tumor sections was performed as previously described by us (15) .
Tumor angiogenesis
Microvessel density (MVD) was determined by CD31 (1:500; sc-1506) immunohistochemical staining of 5μm paraffin embedded tumor sections (25). CD31-positive vessels were counted in 5-6 specimens per group (five fields/sample) using a 20x objective and an ocular grid (0.25 mm 2 per field). CD31 immunoblotting of whole-tumor lysates was also performed (26, 27). 
Western blotting
Homogenized tissue samples and cells were sonicated and lysed in a modified radioimmunoprecipitation assay buffer and processed for immunoblot analysis as previously described (27).
Tumor-Cell Transendothelial Migration Assay
HUVEC (5×10 4 ) were grown to confluence (72h) on top of an 8-μm-pore size gelatincoated membrane (Transwells; BD Biosciences). 1×10 5 [ 3 H]Thymidine labeled or mCherry labeled B16F10 cells in 500μl of 0.1%BSA-DMEM were added to the transwell inserts. Serum-free NIH3T3 conditioned medium (48h) was used as a chemoattractant. After 6h, transwells were washed with PBS and wiped with cotton swabs. Membranes were removed and the amount of radioactivity determined by liquid scintillation counting (LSC) (30). Alternatively, inserts were fixed with 4% PFA, wiped with cotton swabs, and mounted onto glass slides. Migrated mCherry-B16F10 cells were imaged by confocal microscopy (LSM510.META.Confocal; Zeiss). 
Tumor-Endothelial Cell Adhesion Assay
TNFα induced ICAM1 and VCAM1 expression in mice
3-4-month-old WT and Cav1KO female mice were IP injected with 25 μg/kg of mouse recombinant TNFα (R&D). After 5 h, mice were sacrificed and lungs were cleared of blood by infusing cold PBS through the right ventricle (32). The lung left lobe was then collected and processed for western blot analysis (27).
Statistical Analysis
Results are represented as means ± SEM. Statistical analysis was performed using GraphPad Software.
RESULTS
Cav1 ablation in mice promotes the growth of B16F10 melanoma cells independently of Cav2
In order to determine whether absence of Cav1 in the skin affects B16F10 cell growth, we examined the growth of B16F10 cells orthotopically (intradermally) implanted in the skin of WT and Cav1KO C57Bl/6 female mice. After 18 days, analysis of tumor size revealed that their growth was enhanced (~2 fold) in Cav1KO mice (Fig. 1A) . Caveolin-2 (Cav2) is normally co-expressed and heteroligomerizes with Cav1. Previous studies have reported reduced Cav2 levels in Cav1KO mice (13) . Thus, the Cav1KO tumor phenotype may be confounded by Cav2 loss or reduced function. Relative to WT and Cav1KO animals, B16F10 cells implanted in the skin of Cav2KO mice grew more slowly (~1.5 fold), indicating that the Cav1KO tumor phenotype was Cav2 independent (Fig.1B) . Similar reductions in tumor growth were observed in subcutaneously injected Cav2KO mice (Fig.S1 ), indicating a growth promoting role for Cav2 in melanoma. CD31 immunohistochemical staining of Cav1KO tumor sections revealed increased MVD relative to WT and Cav2KO tumors, respectively. These results were corroborated by CD31 immunoblots of whole tumors lysates (Fig.1C) . Taken together, these findings suggest that growth of B16F10 in Cav1KO mice correlates with their MVD and this effect is independent of Cav2.
Absence of Cav1 but not Cav2 in dermal fibroblasts enhances the growth of melanoma cells in co-injection experiments
Dermal fibroblasts are the main cell components of the skin important in maintaining the normal physiological functions of this organ. To determine whether loss of Cav1 in dermal fibroblasts was sufficient to recapitulate the tumor phenotype observed in Cav1KO mice, dermal xenografts were established in nude mice by coinjecting WT and Cav1KO neonatal dermal fibroblasts with B16F10 melanoma cells at 5:1 ratios. After 14 days, analysis of tumor size showed that Cav1KO fibroblasts promoted the growth of B16F10 cells. S100b immunohistochemical staining (melanoma cell marker) and trichrome staining of tumor sections showed that collagen deposition and/or stromal cell proliferation was unchanged in B16F10/WT and B16F10/Cav1KO tumors ( Fig.2A) . In contrast, the growth of tumors resulting from coinjecting B16F10/Cav2KO fibroblasts was comparable to the growth of their controls. Interestingly, immunoblot analysis revealed that Cav1 expression was maintained in Cav2KO fibroblasts whereas Cav2 levels were slightly diminished in Cav1KO fibroblasts (Fig.2B) . The tumor promoting role of Cav1 deficient fibroblasts was further demonstrated by coinjecting human A-375 melanoma cells with hTBJ1-shCtrl or hTBJ1-shCAV1 fibroblasts in nude mice (Fig.2C) . Together, these results demonstrate that Cav1 deficient fibroblasts, but not Cav2KO cells, are sufficient to recapitulate the tumor phenotype of Cav1KO mice.
Fibroblasts lacking Cav1 promote the growth of melanoma cells in non-contact cocultures but not in direct-contact cocultures
To investigate possible mechanisms whereby Cav1 deficient fibroblasts may promote B16F10 tumor growth, we cocultured (under cell-cell contact conditions) mCherry-B16F10 cells with serum-activated WT or Cav1KO dermal fibroblasts or mCherry-A375 cells with serum-activated eGFP-labeled hTBJ1-shCtrl or hTBJ1-shCAV1 at 1:5 ratios in low-serum medium (1% FBS). After 48h and 72h, FACS analysis of mCherry-B16F10 or mCherry-A375 cells revealed that Cav1 deficient fibroblasts were unable to promote the growth of melanoma cells under these conditions. Immunoblot analysis of primary Cav1KO FBs or shCAV1 FBs confirms absence/knockdown of Cav1 protein relative to WT and shCtrl FBs, respectively. Furthermore, primary cultures were negative for the keratinocyte cell marker K14, confirming the purity of these cell populations ( Fig.3A and B) . In contrast, a [ 3 H]Thymidine incorporation assay demonstrates that proliferation of melanoma cells was significantly increased when cocultured (72h) with fibroblasts lacking Cav1 under non contact conditions (Fig.3C ). These findings suggest that soluble secreted factors may be mediating the pro-proliferative effects of Cav1 deficient fibroblasts on melanoma cells.
Serum-activated Cav1KO dermal fibroblasts display increased amounts of protumorigenic cytokines
In order to determine whether Cav1 expression may regulate secreted soluble factors in fibroblasts, a cytokine array was performed on conditioned medium (CM) from serum activated WT and Cav1KO dermal fibroblasts. CM from serum activated Cav1KO fibroblasts displays increased expression of ShhN, bFGF and MMP2/3, cytokines known to promote proliferation, invasion and angiogenesis during melanomagenesis. Decoy receptors (HGFR, VEGFR2) and an inhibitor of MMPs (TIMP1) were reduced in Cav1KO CM (Fig.  4A ). Increased expression of ShhN was also confirmed by ELISA assay and by immunoblot analysis of CM and cell lysates from Cav1 deficient fibroblasts (Fig.4A) . In addition, B16F10 cells incubated with CM from serum-activated Cav1KO fibroblasts (48h) displays increased cell proliferation/growth and hyperactivation of the Shh signaling pathway as evidenced by increased Cyclin D1/A and Gli-1 expression (a Shh target gene) and by increased [ 3 H]-Thymidine incorporation and MTT assay (Fig.4B) . Similar outcomes were obtained when A-375 cells were incubated with CM from serum-activated hTBJ1-sh-CAV1 cells (Fig.4A and C) . Thus, our results indicate that fibroblasts lacking Cav1 secrete factors that promote proliferation, invasion and angiogenesis.
Inhibition of Shh signaling pathway in melanoma cells reverses the proproliferative/ protumorigenic effects of fibroblasts lacking Cav1
Recent studies have shown aberrant activation of Shh signaling in several cancer types including melanoma (33). To determine whether pharmacological inhibition of the Shh pathway in B16F10 cells can reverse the pro-proliferative effect of Cav1KO-CM, we performed a [ 3 H]-thymidine incorporation assay on melanoma cells incubated for 48h with Cav1KO-CM containing Cyclopamine, a specific inhibitor of the Shh pathway. Our results show that low concentrations of Cyclopamine (5-10 μM) were effective in blocking the proproliferative effects of Cav1KO-CM on B16F10 melanoma cells. Interestingly, the proliferation of B16F10 cells incubated with WT-CM containing Cyclopamine remains unchanged (Fig.5A) . Similarly, Cyclopamine prevented the pro-proliferative effects of CM from serum-activated hTBJ1-shCAV1 cells on A-375 human melanoma cells (Fig.5B) . To examine whether inhibition of the Shh signaling pathway in B16F10 melanoma cells abolishes the protumorigenic properties of Cav1 deficient fibroblasts in vivo, we stably silenced the Gli-1 gene by lentiviral shRNA technology. Complete Gli-1 knockdown and reduced Gli-1 expression levels were achieved in absence and presence of Shh, respectively. Similar Gli-1 expression levels were also observed in A-375 cells treated with Shh, suggesting a fully functional Shh signaling pathway in both melanoma cell types (Fig.5C,  left) . Coinjection experiments performed as in Fig.2A demonstrated that Gli-1 knockdown in B16F10 cells was sufficient to reverse the tumor promoting effects of Cav1 deficient fibroblasts (Fig.5C, right) . In summary, these data show that Shh heterotypic signaling is critical for B16F10 melanoma cell proliferation and melanoma tumor growth when Cav1 is absent in dermal fibroblasts.
Cav1 deficiency inhibits lung colonization and transendothelial migration of B16F10 melanoma cells
Given the absence of spontaneous metastasis formation in B16F10 orthotopic tumor bearing WT and Cav1KO mice (data not shown), we i.v. injected 10 5 B16F10 cells to determine their ability to colonize the lungs of WT and Cav1KO mice (experimental metastasis assay). Interestingly, the ability of B16F10 cells to colonize the lungs of Cav1KO mice was significantly impaired (Fig.6A) . To identify possible mechanisms accounting for these findings, we determined the ability of mCherry labeled or [ 3 H]thymidine labeled B16F10 cells to transmigrate through a monolayer of lentivirally transduced shCtrl and shCAV1-HUVEC cells. Consistent with our in vivo data, the ability of B16F10 cells to adhere to and to transmigrate through a HUVEC monolayer was significantly reduced in CAV1 knockdown cells (Fig.6B and C) . Interestingly, incubation of HUVEC with ICAM-1 and VCAM-1 antibodies reduced the adhesion of B16F10 cells to levels similar to those observed with the HUVEC-shCAV1, suggesting a critical role for Cav1 in regulating the process of metastatic extravasation (Fig.6C, left) . TNFα induced VCAM-1 and ICAM-1 expression has been described as being critical in cancer cells-endothelium interactions (34). Interestingly, our in vitro results were corroborated by reduced VCAM-1 and ICAM-1 expression levels in lungs of 5h-TNFα-treated Cav1KO mice (Fig.6C, right) . Collectively, these results demonstrate that CAV1 has a key role in the endothelium and regulates processes such as adhesion and transmigration that are ultimately relevant for the establishment of lung metastases in vivo.
DISCUSSION
In the current study, we show that Cav1 gene disruption promotes the growth of B16F10 melanoma cells in the skin of mice, whereas it inhibits the formation of lung metastases. Our data indicate that lack of Cav1 in dermal fibroblasts contributes to primary melanoma tumor growth by increased paracrine cytokine signaling, whereas the inability of B16F10 cells to form lung metastases is attributed to defects in VCAM1 and ICAM1 mediated adhesion to endothelial cells. Although the function of Cav1 has been recently examined in melanoma cancer cells (15, 35) , the role of stromal Cav1 in melanoma tumor growth and metastasis remains less well studied. Here, we demonstrate that the difference in tumor growth seen in Cav1KO and Cav2KO mice seems to correlate well with differences in their microvascular density. However, in contrast to our results, previous studies have shown reduced tumor growth and reduced MVD in Cav1KO mice subcutaneously injected with B16F10 cells (36, 17) , indicating that the injection site (intradermal vs. subcutaneous) and consequently the different tumor microenvironments may significantly affect melanoma tumor growth (7, 44) . Although our findings are consistent with other studies showing a direct positive relationship between lack of Cav1 and higher microvascular density in vivo (11, 50), we cannot exclude the possibility that other stromal factors other than the endothelial cells are responsible for the Cav1KO and Cav2KO tumor phenotypes. Dermal fibroblasts, in fact, are abundant cellular components of the skin and they exert important biological functions to maintain normal skin homeostasis (37) . Our coinjection experiments show that absence of Cav1 in dermal fibroblasts is sufficient to recapitulate the tumor phenotype of Cav1KO mice. Interestingly, Cav2 deficient fibroblasts that express Cav1 (14) , fail to replicate the tumor phenotype of Cav2KO (and Cav1KO) mice, indicating that the tumor promoting effects of Cav1 deficient fibroblasts were Cav2 independent.
Based on these findings, we postulated that Cav1 deficient fibroblasts promote the growth of melanoma cells by either direct cell-cell contact or paracrine signaling. To test this hypothesis we performed direct and indirect cocultures of fibroblasts and melanoma cells. Interestingly, our results from coculture experiments suggest that the growth promoting features of Cav1 deficient fibroblasts may be attributed to enhanced paracrine signaling that does not require direct cell-cell contact. However, the inability of Cav1 deficient fibroblasts to promote the growth of melanoma cells in direct cell-cell contact cocultures can most likely be attributed to direct cell-cell contact inhibitory mechanisms exerted by normal fibroblasts (primary and/or immortalized cells) that are able to overcome the proproliferative effects of secreted soluble factors. To identify possible secreted factors we performed a cytokine array on conditioned medium from serum activated dermal fibroblasts. The increased secretion of cytokines such as ShhN, MMP2/3 and bFGF and the reduced expression of VEGFR2, HGF-R (decoy receptors (38) ) and TIMP1 (MMPs inhibitor) observed in Cav1KO dermal fibroblasts further confirms their protumorigenic phenotype, and this cytokine signature correlates well with the tumor phenotype of Cav1KO mice. In addition, these results are in agreement with many published studies that identified similar factors associated with the stromal remodeling of tumors (3, 39) . A key finding of our study is the increased amount of the soluble form of the Shh protein (ShhN) observed in the CM of serum activated Cav1KO dermal fibroblasts. Aside from having an essential role in embryonic development, Shh modulates many aspects of skin biology including woundhealing (40) , proliferation, and transformation (41) . Furthermore, although Shh has been described to mainly function in an autocrine manner in melanomagenesis (33), it is now becoming increasingly evident that Shh may contribute to tumor growth in a paracrine manner (42) . Our results, showing increased DNA synthesis and increased Gli-1 expression in melanoma cells incubated with CM from Cav1 deficient FBs, provide evidence that absence of Cav1 enhances Shh heterotypic signaling. Consequently, the pro-proliferative and protumorigenic effects of Cav1 deficient fibroblasts are reversed by inhibiting the Shh pathway with cyclopamine and by silencing Gli-1 in B16F10 cells. Another important key finding of our study is the inability of B16F10 cells to form lung metastases in Cav1KO mice. The dissemination of cancer cells to metastatic sites is a stepwise process that begins with the invasion of the dermis surrounding the primary tumor and ends with metastatic extravasation and colonization of ectopic sites (43, 7) . Metastatic extravasation from the bloodstream is a critical last step of the metastatic cascade that similarly to leukocyte transmigration requires the firm binding of cancer cells to the endothelial adhesion molecules VCAM-1 and ICAM-1. Blockade of VCAM-1 and ICAM-1 mediated interactions has been shown to effectively prevent the development of metastasis in a preclinical setting (31, 45, 46) . Given these considerations, our adhesion assay results and our data showing reduced ICAM-1 and VCAM-1 expression in the lungs of TNFα treated Cav1KO mice, suggest that the inability of B16F10 cells to form metastases and to extravasate may be attributed to defects in VCAM1 and ICAM1 mediated adhesion to endothelial cells. Given our primary tumor results, the metastasis phenotype of Cav1KO mice seems quite paradoxical. However, recent work reveals that Cav1KO mice display several non cancer related phenotypes that support our observations. For instance, previous studies have shown that the resistance of Cav1KO mice to atherosclerosis development may be attributed to impaired endothelial VCAM-1 and ICAM-1 functions that ultimately result in reduced inflammation and impaired macrophage migration throughout the endothelium (47) (48) (49) . Thus, it appears that similar endothelial defects may cause resistance to atherosclerosis and reduce melanoma metastasis in Cav1KO mice.
In summary, we show that loss of Cav1 promotes the growth of B16F10 tumors in the skin, while it suppresses B16F10 lung metastasis. Mechanistically, this phenotype is associated with enhanced paracrine cytokine signaling in Cav1KO dermal fibroblasts and with defects in endothelial cell mediated transmigration of melanoma cells (Fig.7) . Thus, these findings support the notion that effective anticancer therapies will have to take into account the complex interactions between cancer cells and their microenvironment in both primary tumors and metastases.
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